Posted by Michael Wonder on 13 Aug 2018
China’s drugs problem spells opportunity for pharma giants
10 August 2018 - Despite escalating global trade tensions, there is at least one area in which China is still opening up—pharmaceuticals.
The country’s Center for Drug Evaluation, China’s version of the FDA, this week made 48 drugs that have already been approved by regulators in the U.S., Japan or Europe eligible for fast-track approval, without additional domestic trials. The move is consistent with Beijing’s policy announced last October to cut red tape around its drug-approval processes.
